5MG
Research vial$76.99

- Lab tested & verified
- Batch COA available
- Fast fulfillment
- U.S. based support
Weight-loss research peptide
24.2%mean weight reduction in Phase 2*
GLP3-R is retatrutide — the triple-agonist studied for weight loss at the GLP-1, GIP and glucagon receptors.


*Phase 2 trial published in NEJM, 2023. Illustrative image. Research use only. Not for human consumption.
Why GLP3-R?
Semaglutide targets GLP-1. Tirzepatide adds GIP. Retatrutide goes further with glucagon-receptor activity, opening a different direction in appetite, energy expenditure and body-weight research.

Appetite & glucose signaling
Insulin & metabolic regulation
Energy expenditure & hepatic function

Published weight-loss research
In a 2023 study published in the New England Journal of Medicine, the highest-dose retatrutide group achieved a mean body-weight reduction of 24.2% at 48 weeks.
This was a controlled clinical trial using an investigational medicine, not Purple Peptides research vials. It does not establish results or safety for personal use.
Choose your research size
$76.99

$142.99

$241.99


How it works
GLP3-R is designed to interact with GLP-1, GIP, and glucagon receptors. This multi-pathway activity is what makes it one of the most interesting compounds in modern research.
Quality & transparency
Make documentation part of your purchase. Review the product's batch-specific Certificate of Analysis for purity and identity testing before choosing your research vial.
How it compares
| Semaglutide | Tirzepatide | GLP3-R | |
|---|---|---|---|
| GLP-1 receptor | |||
| GIP receptor | |||
| Glucagon receptor |
Frequently asked questions
GLP3-R is retatrutide, an investigational peptide studied as an agonist at the GLP-1, GIP and glucagon receptors.
Certificates of Analysis are available on the Purple Peptides testing page. Check the certificate for the specific product and lot.
Tirzepatide targets GLP-1 and GIP. Retatrutide adds glucagon-receptor activity, which is studied for its effect on energy expenditure.
Select the research quantity appropriate for your laboratory protocol. Available vial sizes are 5 mg, 10 mg and 30 mg.
In the Phase 2 trial published in NEJM (2023), the highest-dose group had mean body-weight reduction of 24.2% at 48 weeks. These clinical findings are not claims for research vials or instructions for personal use.
No. Retatrutide is investigational and not approved for medical use. Products are strictly for laboratory research, not human consumption.

Your next research purchase
5 mg, 10 mg or 30 mg. Find your research vial.
For research use only. Not for human consumption.